- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03690388
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
March 20, 2024 updated by: Exelixis
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
187
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Caba, Argentina, C1012AAR
- Exelixis Clinical Site #97
-
Córdoba, Argentina, X5000AVE
- Exelixis Clinical Site #129
-
-
Buenos Aires
-
Pergamino, Buenos Aires, Argentina, B2700CPM
- Exelixis Clinical Site #96
-
-
-
-
-
Herston, Australia, 4029
- Exelixis Clinical Site #12
-
-
New South Wales
-
St. Leonards, New South Wales, Australia, 2065
- Exelixis Clinical Site #17
-
Waratah, New South Wales, Australia, 2298
- Exelixis Clinical Site #25
-
-
South Australia
-
Bedford Park, South Australia, Australia, 5042
- Exelixis Clinical Site #86
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Exelixis Clinical Site #24
-
-
-
-
-
Salzburg, Austria, 5020
- Exelixis Clinical Site #62
-
Vienna, Austria, 1090
- Exelixis Clinical Site #119
-
-
-
-
-
Anderlecht, Belgium, 1070
- Exelixis Clinical Site #90
-
Brussels, Belgium, 1200
- Exelixis Clinical Site #31
-
Edegem, Belgium, 2650
- Exelixis Clinical Site #26
-
Edegem, Belgium, 2650
- Exelixis Clinical Site #74
-
Gent, Belgium, 9000
- Exelixis Clinical Site #100
-
Namur, Belgium, 5000
- Exelixis Clinical Site #27
-
-
-
-
-
Rio De Janeiro, Brazil, 20231-050
- Exelixis Clinical Site #92
-
Sao Paulo, Brazil, 01246-000
- Exelixis Clinical Site #47
-
-
Parana
-
Cascavel, Parana, Brazil, 85806-300
- Exelixis Clinical Site #35
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-903
- Exelixis Clinical Site #39
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90050-170
- Exelixis Clinical Site #140
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90110-270
- Exelixis Clinical Site #38
-
-
Sao Paulo
-
Sao Jose do Rio Preto, Sao Paulo, Brazil, 15090-000
- Exelixis Clinical Site #40
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brazil, 14051-140
- Exelixis Clinical Site #116
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Exelixis Clinical Site #20
-
Edmonton, Alberta, Canada, T6G 1Z2
- Exelixis Clinical Site #18
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Exelixis Clinical Site #107
-
Toronto, Ontario, Canada, M5G 2M9
- Exelixis Clinical Site #83
-
-
-
-
-
Osijek, Croatia, 31000
- Exelixis Clinical Site #145
-
Zagreb, Croatia, 10000
- Exelixis Clinical Site #137
-
Zagreb, Croatia, 10000
- Exelixis Clinical Site #138
-
-
-
-
-
Brno, Czechia, 656 53
- Exelixis Clinical Site #105
-
Olomouc, Czechia, 779 00
- Exelixis Clinical Site #104
-
-
-
-
-
Besançon, France, 25030
- Exelixis Clinical Site #102
-
Lyon Cedex 08, France, 69373
- Exelixis Clinical Site #91
-
Nice, France, 06189
- Exelixis Clinical Site #82
-
Paris, France, 75013
- Exelixis Clinical Site #152
-
Strasbourg Cedex, France, 67065
- Exelixis Clinical Site #95
-
-
Bourgogne-Franche-Comte
-
Dijon, Bourgogne-Franche-Comte, France, 21079
- Exelixis Clinical Site #32
-
-
Ile De France
-
Villejuif, Ile De France, France, 94805
- Exelixis Clinical Site #44
-
-
Nouvelle - Aquitaine
-
Bordeaux, Nouvelle - Aquitaine, France, 33075
- Exelixis Clinical Site #67
-
-
Pays De La Loire
-
Angers, Pays De La Loire, France, 4933
- Exelixis Clinical Site #45
-
-
Provence-Alpes-Cote d'Azur
-
Marseille, Provence-Alpes-Cote d'Azur, France, 13915
- Exelixis Clinical Site #72
-
-
-
-
-
Aachen, Germany, 52074
- Exelixis Clinical Site #155
-
Bonn, Germany, 53127
- Exelixis Clinical Site #131
-
Essen, Germany, 45147
- Exelixis Clinical Site #154
-
Freiburg, Germany, 79106
- Exelixis Clinical Site #160
-
Hamburg, Germany, 20246
- Exelixis Clinical Site #159
-
München, Germany, 81377
- Exelixis Clinical Site #139
-
-
Baden-Württemberg
-
Tübingen, Baden-Württemberg, Germany, 72076
- Exelixis Clinical Site #121
-
-
Bayern
-
Würzburg, Bayern, Germany, 97080
- Exelixis Clinical Site #156
-
-
Hesse
-
Marburg, Hesse, Germany, 35043
- Exelixis Clinical Site #125
-
-
Lower Saxony
-
Hannover, Lower Saxony, Germany, 30625
- Exelixis Clinical Site #163
-
-
Sachsen-Anhalt
-
Magdeburg, Sachsen-Anhalt, Germany, 39120
- Exelixis Clinical Site #124
-
-
Saxony
-
Dresden, Saxony, Germany, 01307
- Exelixis Clinical Site #151
-
-
-
-
-
Hong Kong, Hong Kong
- Exelixis Clinical Site #28
-
-
-
-
-
Budapest, Hungary, 1122
- Exelixis Clinical Site #46
-
Pecs, Hungary, 7624
- Exelixis Clinical Site #37
-
-
-
-
-
Haifa, Israel, 3109601
- Exelixis Clinical Site #43
-
Jerusalem, Israel, 9112001
- Exelixis Clinical Site #41
-
Petah tikva, Israel, 4941492
- Exelixis Clinical Site #58
-
-
-
-
-
Milano, Italy, 20133
- Exelixis Clinical Site #103
-
Milano, Italy, 20141
- Exelixis Clinical Site #110
-
Milano, Italy, 20149
- Exelixis Clinical Site #115
-
Napoli, Italy, 80131
- Exelixis Clinical Site #108
-
Napoli, Italy, 80131
- Exelixis Clinical Site #56
-
Padova, Italy, 35128
- Exelixis Clinical Site #123
-
Roma, Italy, 00144
- Exelixis Clinical Site #87
-
Roma, Italy, 00161
- Exelixis Clinical Site #127
-
Siena, Italy, 53100
- Exelixis Clinical Site #111
-
-
CT
-
Catania, CT, Italy, 95122
- Exelixis Clinical Site #135
-
-
Catania
-
Viagrande, Catania, Italy, 95029
- Exelixis Clinical Site #109
-
-
Forlì - Cesena
-
Meldola, Forlì - Cesena, Italy, 47017
- Exelixis Clinical Site #132
-
-
GE
-
Genova, GE, Italy, 16132
- Exelixis Clinical Site #144
-
-
Milano
-
Rozzano, Milano, Italy, 20089
- Exelixis Clinical Site #143
-
-
PI
-
Pisa, PI, Italy, 56124
- Exelixis Clinical Site #29
-
-
TO
-
Torino, TO, Italy, 10126
- Exelixis Clinical Site #120
-
-
-
-
-
Busan, Korea, Republic of, 49267
- Exelixis Clinical Site #70
-
Gyeonggi-do, Korea, Republic of, 10408
- Exelixis Clinical Site #79
-
Seoul, Korea, Republic of, 03080
- Exelixis Clinical Site #36
-
Seoul, Korea, Republic of, 05505
- Exelixis Clinical Site #34
-
-
-
-
-
Ciudad de Mèxico, Mexico, 06100
- Exelixis Clinical Site #133
-
Ciudad de México, Mexico, 03100
- Exelixis Clinical Site #147
-
Ciudad de México, Mexico, 06700
- Exelixis Clinical Site #148
-
San Luis Potosí, Mexico, 78200
- Exelixis Clinical Site #161
-
-
Chiapas
-
Tuxtla Gutiérrez, Chiapas, Mexico, 29038
- Exelixis Clinical Site #158
-
-
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1081 HV
- Exelixis Clinical Site #128
-
-
Zuid-Holland
-
Leiden, Zuid-Holland, Netherlands, 2333 ZA
- Exelixis Clinical Site #117
-
-
-
-
Mazowieckie
-
Warszawa, Mazowieckie, Poland, 02-781
- Exelixis Clinical Site #15
-
-
Slaskie
-
Gliwice, Slaskie, Poland, 44-101
- Exelixis Clinical Site #61
-
-
Wielkopolskie
-
Poznan, Wielkopolskie, Poland, 60-355
- Exelixis Clinical Site #59
-
-
-
-
-
Bucuresti, Romania, 011863
- Exelixis Clinical Site #146
-
-
Cluj
-
Cluj-Napoca, Cluj, Romania, 400015
- Exelixis Clinical Site #149
-
-
Dolj
-
Craiova, Dolj, Romania, 200385
- Exelixis Clinical Site #150
-
-
Timis
-
Timişoara, Timis, Romania, 300166
- Exelixis Clinical Site #142
-
-
-
-
-
Moscow, Russian Federation, 117036
- Exelixis Clinical Site #49
-
Moscow, Russian Federation, 121309
- Exelixis Clinical Site #53
-
Moscow, Russian Federation, 125284
- Exelixis Clinical Site #84
-
Moscow, Russian Federation, 155478
- Exelixis Clinical Site #85
-
Omsk, Russian Federation, 644013
- Exelixis Clinical Site #106
-
Saint Petersburg, Russian Federation, 198255
- Exelixis Clinical Site #89
-
Samara, Russian Federation, 443031
- Exelixis Clinical Site #52
-
Yaroslavl, Russian Federation, 150054
- Exelixis Clinical Site #66
-
-
Kaluzhiskiy Region
-
Obninsk, Kaluzhiskiy Region, Russian Federation, 249036
- Exelixis Clinical Site #48
-
-
Kursk Region
-
Kislino, Kursk Region, Russian Federation, 305524
- Exelixis Clinical Site #55
-
-
Tyumen Region
-
Tyumen, Tyumen Region, Russian Federation, 625041
- Exelixis Clinical Site #157
-
-
-
-
-
Barcelona, Spain, 08035
- Exelixis Clinical Site #14
-
Barcelona, Spain, 08036
- Exelixis Clinical Site #99
-
Madrid, Spain, 28027
- Exelixis Clinical Site #114
-
Madrid, Spain, 28033
- Exelixis Clinical Site #30
-
Madrid, Spain, 28034
- Exelixis Clinical Site #13
-
Madrid, Spain, 28040
- Exelixis Clinical Site #16
-
Madrid, Spain, 28041
- Exelixis Clinical Site #33
-
Madrid, Spain, 28046
- Exelixis Clinical Site #73
-
Madrid, Spain, 28050
- Exelixis Clinical Site #23
-
Málaga, Spain, 29010
- Exelixis Clinical Site #81
-
-
-
-
-
Tainan, Taiwan, 704
- Exelixis Clinical Site #136
-
Tainan, Taiwan, 71004
- Exelixis Clinical Site #112
-
Taipei, Taiwan, 10002
- Exelixis Clinical Site #77
-
Taipei, Taiwan, 11490
- Exelixis Clinical Site #101
-
-
-
-
Bangkok
-
Bangkok Noi, Bangkok, Thailand, 10700
- Exelixis Clinical Site #126
-
Pathum Wan, Bangkok, Thailand, 10330
- Exelixis Clinical Site #122
-
Ratchathewi, Bangkok, Thailand, 10400
- Exelixis Clinical Site #141
-
-
Songkla
-
Hat Yai, Songkla, Thailand, 90110
- Exelixis Clinical Site #130
-
-
-
-
-
Manchester, United Kingdom, M20 4BX
- Exelixis Clinical Site #65
-
Sheffield, United Kingdom, S10 2SJ
- Exelixis Clinical Site #57
-
-
England
-
Birmingham, England, United Kingdom, B15 2TH
- Exelixis Clinical Site #88
-
Bristol, England, United Kingdom, BS2 8ED
- Exelixis Clinical Site #71
-
London, England, United Kingdom, SW3 6JJ
- Exelixis Clinical Site #162
-
Oxford, England, United Kingdom, OX3 7LE
- Exelixis Clinical Site #51
-
-
Scotland
-
Aberdeen, Scotland, United Kingdom, AB25 2ZN
- Exelixis Clinical Site #64
-
Glasgow, Scotland, United Kingdom, G12 0YN
- Exelixis Clinical Site #50
-
-
Wales
-
Cardiff, Wales, United Kingdom, CF14 2TL
- Exelixis Clinical Site #60
-
-
-
-
California
-
Newport Beach, California, United States, 92658
- Exelixis Clinical Site #2
-
Sacramento, California, United States, 95817
- Exelixis Clinical Site #98
-
San Francisco, California, United States, 94115
- Exelixis Clinical Site #69
-
Stanford, California, United States, 94305
- Exelixis Clinical Site #10
-
Torrance, California, United States, 90502
- Exelixis Clinical Site #3
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Exelixis Clinical Site #9
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Exelixis Clinical Site #21
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Exelixis Clinical Site #4
-
-
Florida
-
Miami, Florida, United States, 33136
- Exelixis Clinical Site #94
-
Orlando, Florida, United States, 32804
- Exelixis Clinical Site #93
-
Tampa, Florida, United States, 33612
- Exelixis Clinical Site #6
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Exelixis Clinical Site #164
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Exelixis Clinical Site #54
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Exelixis Clinical Site #153
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Exelixis Clinical Site #80
-
Detroit, Michigan, United States, 48201
- Exelixis Clinical Site #78
-
Detroit, Michigan, United States, 48202
- Exelixis Clinical Site #22
-
-
Missouri
-
Columbia, Missouri, United States, 65212
- Exelixis Clinical Site #63
-
Saint Louis, Missouri, United States, 63110
- Exelixis Clinical Site #42
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Exelixis Clinical Site #11
-
-
New Jersey
-
Morristown, New Jersey, United States, 07962
- Exelixis Clinical Site #118
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Exelixis Clinical Site #76
-
Durham, North Carolina, United States, 27710
- Exelixis Clinical Site #19
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Exelixis Clinical Site #7
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18015
- Exelixis Clinical Site #5
-
Philadelphia, Pennsylvania, United States, 19104
- Exelixis Clinical Site #1
-
Pittsburgh, Pennsylvania, United States, 15232
- Exelixis Clinical Site #75
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Exelixis Clinical Site #134
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Exelixis Clinical Site #68
-
-
Texas
-
Houston, Texas, United States, 77030
- Exelixis Clinical Site #8
-
-
Washington
-
Seattle, Washington, United States, 98109
- Exelixis Clinical Site #113
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of Differentiated Thyroid Cancer (DTC)
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Previously treated with or deemed ineligible for treatment with Iodine- 131 for differentiated thyroid cancer (DTC)
- Previously treated with at least one of the following vascular endothelial growth factor receptor (VEGFR)-targeting tyrosine kinase inhibitor (TKI) agents for DTC: lenvatinib or sorafenib. Note: Up to two prior VEGFR-targeting TKI agents are allowed
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Exclusion Criteria:
- Prior treatment with any of the following: Cabozantinib; Selective small-molecule v-raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitor; More than 2 VEGFR-targeting TKI agents; More than 1 immune checkpoint inhibitor therapy; 1 systemic chemotherapy regimen (given as single agent or in combination with another chemotherapy agent)
- Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks or 5 half-lives of the agent, whichever is longer, before randomization
- Receipt of any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before randomization
- Receipt of radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before randomization.
- Known brain metastases or cranial epidural disease unless adequately treated
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cabozantinib
cabozantinib (60 mg) once daily orally (qd)
|
Tablets containing 60-mg or 20-mg cabozantinib once daily orally.
Other Names:
|
Placebo Comparator: Placebo
placebo once daily orally (qd)
|
Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS)
Time Frame: Up to approximately twenty months after the first subject is randomized. Time from randomization to the earlier of the following events: radiographic PD as determined by the blinded independent central review (BIRC) or death due to any cause.
|
Time to the earlier of either radiographic progressive disease (PD) or death from any cause.
|
Up to approximately twenty months after the first subject is randomized. Time from randomization to the earlier of the following events: radiographic PD as determined by the blinded independent central review (BIRC) or death due to any cause.
|
Objective Response Rate (ORR)
Time Frame: Six months after 100 subjects are randomized. Time from randomization to best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BIRC per RECIST 1.1.
|
Proportion of subjects with the best overall response of complete response (CR) or partial response (PR).
|
Six months after 100 subjects are randomized. Time from randomization to best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BIRC per RECIST 1.1.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 5, 2018
Primary Completion (Actual)
August 19, 2020
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
September 26, 2018
First Submitted That Met QC Criteria
September 27, 2018
First Posted (Actual)
October 1, 2018
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
March 20, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XL184-311
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Differentiated Thyroid Cancer
-
Thomas Jefferson UniversityActive, not recruitingDifferentiated Thyroid Cancer (DTC) | Poorly Differentiated Thyroid CancerUnited States
-
University of PennsylvaniaCompletedMetastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid CancerUnited States
-
National Cancer Institute (NCI)TerminatedThyroid Neoplasms | Differentiated Thyroid Cancer | Poorly Differentiated and Undifferentiated Thyroid CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedThyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid CancerUnited States
-
Children's Hospital of PhiladelphiaBayerRecruitingCancer | Pediatric Cancer | Differentiated Thyroid Cancer | Cancer, ThyroidUnited States
-
Istituti Clinici Scientifici Maugeri SpAMerck Sharp & Dohme LLCRecruiting
-
National Taiwan University HospitalRecruitingDifferentiated Thyroid CancerTaiwan
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdActive, not recruitingDifferentiated Thyroid CancerChina
-
Genzyme, a Sanofi CompanyCompletedEvaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer (VERIFY)Differentiated Thyroid CancerUnited States, Sweden, Brazil, Italy, Poland, Spain, China, Russian Federation, France, Japan, Denmark, Czechia
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdTerminatedDifferentiated Thyroid CancerChina
Clinical Trials on Cabozantinib
-
University of BolognaIpsen; Bioikos Ambiente Srl; AOU S.Orsola Malpighi-Unit of Oncologic Molecular... and other collaboratorsUnknownNon Small Cell Lung CancerItaly
-
ExelixisCompletedCancer | NSCLC | Solid TumorsJapan
-
University of WashingtonNational Cancer Institute (NCI); Prostate Cancer FoundationTerminatedRecurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States
-
Karsten GavenisRecruitingNeuroendocrine Tumors | Neuroendocrine CarcinomaGermany, Austria
-
Institut für Klinische Krebsforschung IKF GmbH...IpsenRecruitingHepatocellular Carcinoma Non-resectable | Metastatic Hepatocellular CarcinomaGermany
-
Istituto Oncologico Veneto IRCCSActive, not recruiting
-
Spanish Oncology Genito-Urinary GroupApices Soluciones S.L.CompletedOld Age; Debility | Renal Carcinoma MetastaticSpain
-
Stephen Chan LamActive, not recruiting
-
ExelixisApproved for marketing
-
University of LeipzigRecruitingHepatocellular CarcinomaGermany